IndiGo’s shares surged despite a Q4 FY26 net loss of Rs 2,536 crore, driven by Middle East conflict disruptions. Analysts remain largely positive, citing the airline’s long-term growth strategy and India’s strong domestic aviation demand, with several maintaining ‘Buy’ ratings and significant upside targets.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,
June 1, 2026